Endpoints News 生物医药· Reynald Castaneda·· 25 天前AI 评分30
BioNTech与DualityBio宣布HER2 ADC药物曲妥珠单抗帕米替尼在HER2阳性乳腺癌患者中显示有限疗效(HR=1.18, p=0.028, ORR=45.3%, mPFS=5.8个月)
BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results
AI 导读
BioNTech与DualityBio宣布,其HER2 ADC药物曲妥珠单抗帕米替尼在HER2阳性乳腺癌患者中显示有限疗效(HR=1.18, p=0.028, ORR=45.3%, mPFS=5.8个月)。该试验为II期剂量优化研究(N=223),结果可能影响后续III期方案设计。
正文
BioNTech and DualityBio are mulling what to do next with trastuzumab pamirtecan in certain breast cancer patients after the antibody-drug conjugate delivered a “statistically significant …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news